Featured Studies Results
Study Type: Treatment
Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)
https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment
Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)
Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment
Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back
Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)
Treatment
Study for relapsed platinum-sensitive ovarian cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)
Treatment
Treatment study for people with advanced or metastatic cancers
Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)
https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer
Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)
Treatment
Phase 3 treatment study for high-risk prostate cancer
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery
Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01
Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)
Treatment
Post-treatment study to monitor for recurrence
Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
https://www.facingourrisk.org/research-clinical-trials/study/370 /comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01
Clinicaltrials.gov identifier:
NCT07044336 (https://clinicaltrials.gov/show/NCT07044336)
Treatment
Phase 3 treatment study for metastatic endometrial cancer
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
https://www.facingourrisk.org/research-clinical-trials/study/408 /treating-advanced-solid-tumors-with-the-rason-inhibitor-daraxonrasib-combined-with-a-targeted-immunotherapy-ivonescimab
Clinicaltrials.gov identifier:
NCT07397338 (https://clinicaltrials.gov/show/NCT07397338)
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/387 /comparing-a-new-drug-palazestrant-to-standard-treatment-for-advanced-breast-cancer
Clinicaltrials.gov identifier:
NCT06016738 (https://clinicaltrials.gov/show/NCT06016738)
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
https://www.facingourrisk.org/research-clinical-trials/study/409 /treating-advanced-solid-tumors-with-a-kras-g12c-mutation-using-targeted-therapies-called-rason-inhibitors
Clinicaltrials.gov identifier:
NCT06128551 (https://clinicaltrials.gov/show/NCT06128551)
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer
Clinicaltrials.gov identifier:
NCT06411691 (https://clinicaltrials.gov/show/NCT06411691)
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
https://www.facingourrisk.org/research-clinical-trials/study/388 /comparing-hormone-therapy-with-and-without-chemotherapy-for-premenopausal-breast-cancer-ofset
Clinicaltrials.gov identifier:
NCT05879926 (https://clinicaltrials.gov/show/NCT05879926)
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab
https://www.facingourrisk.org/research-clinical-trials/study/362 /testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)
Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.